Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
radioligand AZD4694 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| radioligand [18F]AZD4694 | DRUG | single dose of iv. admin. 1-2 times per subject |
| radioligand [11C]AZD2184 | DRUG | single dose of iv admin. 1 time per subject |
Inclusion Criteria: * Alzheimer's Disease patients - 50-85 years, mild to moderate AD: MMSE ≥16 and ≤ 26, clinical progression of AD over 12 months. * Healthy volunteers: - 50-75 years * BMI 18 and 30 m2/kg * Clinically normal physical findings including supine blood pressure and pulse rate. Exclu...
Top 20 of 24 competitors
AZD4694 is a radioligand being developed by AstraZeneca PLC for use in Alzheimer's disease. It is a small molecule in Phase 1 development. The drug is intended for use in positron emission tomography (PET) imaging to detect amyloid plaques in the brain.
AZD4694 is a radioligand, meaning it is a radioactive compound designed to bind to a specific target. It is a candidate PET ligand for Aβ amyloid, which is a protein that accumulates in the brains of people with Alzheimer's disease. By binding to amyloid, it allows visualization of amyloid plaques via PET imaging.
AZD4694 is in Phase 1 clinical development. There is one completed Phase 1 trial with a total enrollment of 26 participants. The trial was not randomized, not double-blind, and had no control group, meaning it was an uncontrolled study.
The Phase 1 trial (NCT00838877) was a PET study comparing [18F]AZD4694 and [11C]AZD2184, both candidate PET ligands for Aβ amyloid. It was an uncontrolled, open-label study conducted in Sweden. Participants were aged 50 years and older, and healthy volunteers were included. The trial has been completed.
AZD4694 is being studied for Alzheimer's disease. Specifically, it is being developed as a PET imaging agent to detect amyloid plaques, which are a hallmark of Alzheimer's pathology. The completed Phase 1 trial included participants with Alzheimer's disease as well as healthy volunteers.
Yes, AZD4694 is also referred to as [18F]AZD4694 when labeled with the radioactive isotope fluorine-18. In the clinical trial, it was studied alongside another radioligand called [11C]AZD2184. The drug is being developed by AstraZeneca.